PCVX

Vaxcyte Inc

62.72

Nov 05 • 1:15 PM ET -2.96 (-4.51%)

Healthcare Biotechnology USA Mid NASD

Nov 04, 7:16 PMVaxcyte beats fiscal Q3 2026 estimates with non-GAAP EPS $-1.99 and highlights positive Phase 3 OPUS-1 data

Peers: PFE MRK GSK SNY NVAX MRNA BNTX VALN VIR EBS

| Held by: VTI IWM VB XBI VBK VXF TCAF IBB IWO SCHA

Scroll to Statements

Index	RUT
Market Cap	9.87B
Enterprise Value	8.80B
Income	-1.15B
Sales	0.00M
Book/sh	16.67
Cash/sh	8.21
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	507
IPO	Jun 12, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.76
P/C	7.64
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.56
Current Ratio	4.56
Debt/Eq	0.09
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-8.14
EPS next Y	-6.74
EPS next Q	-1.94
EPS this Y	-40.83%
EPS next Y	14.99%
EPS next 5Y	-3.15%
EPS past 3/5Y	-17.82% -26.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	-83.87%
Sales Y/Y TTM	-
EPS Q/Q	-27.66%
Sales Q/Q	-
Earnings	Nov 04 AMC
EPS/Sales Surpr.	5.88% -

Insider Own	2.29%
Insider Trans	-4.54%
Inst Own	105.96%
Inst Trans	2.32%
ROA	-37.28%
ROE	-42.68%
ROIC	-42.64%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.87%
SMA50	1.71%
SMA200	9.41%
Trades

Shs Outstand	157.39M
Shs Float	153.78M
Short Float	9.51%
Short Ratio	6.93
Short Interest	14.62M
52W High	90.75 -30.89%
52W Low	39.87 57.31%
Volatility	4.54% 5.34%
ATR (14)	3.53
RSI (14)	50.32
Beta	1.29
Rel Volume	0.45
Avg Volume	2.11M
Volume	573,666

Perf Week	0.18%
Perf Month	-6.33%
Perf Quarter	8.01%
Perf Half Y	21.83%
Perf YTD	35.93%
Perf Year	55.56%
Perf 3Y	23.59%
Perf 5Y	147.81%
Perf 10Y	-
Recom	1.20
Target Price	116.40
Prev Close	65.68
Price	62.72
Change %	-4.51%

Consensus

Strong Buy

Avg. Price Target

$116.40

Implied Upside

+85.6%

Analysts9incl. previous ratings

Rating Distribution8 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 07, 2026	Reiterated	NNeedham	Buy	$90 → $110	+75.4%
Sep 12, 2025	Initiated	GGoldman	Neutral	$38	-39.4%
Apr 22, 2025	Initiated	CCantor Fitzgerald	Overweight
Dec 20, 2024	Initiated	GGoldman	Buy	$135	+115.2%
Dec 07, 2023	Initiated	MMizuho	Buy	$69	+10.0%
Apr 18, 2023	Initiated	TTD Cowen	Outperform
Jan 03, 2023	Reiterated	NNeedham	Buy	$52 → $58	-7.5%
Dec 15, 2022	Initiated	GGuggenheim	Buy	$66	+5.2%
Nov 17, 2022	Initiated	BBTIG Research	Buy	$69	+10.0%
Dec 29, 2021	Resumed	JJefferies	Buy	$50	-20.3%
Jun 24, 2021	Resumed	JJefferies	Buy	$50	-20.3%
Jul 07, 2020	Initiated	NNeedham	Buy	$40	-36.2%
Jul 07, 2020	Initiated	CCantor Fitzgerald	Overweight	$55	-12.3%
Jul 07, 2020	Initiated	BBofA Securities	Buy	$37	-41.0%

Nov-04-26 04:05PM	Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +8.01%
Oct-09-26 08:09PM	BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push (Stocktwits) +9.79%
04:05PM	Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes (GlobeNewswire)
Oct-06-26 10:48PM	Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes (GlobeNewswire) -9.65%
04:38PM	Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers (Investor's Business Daily)
11:31AM	Loading…
11:31AM	As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%) (TIKR)
08:44AM	Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results (Quartz)
02:10AM	MARKETS LIVE: US futures climb after Nasdaq record close (Proactive)
01:38AM	Pfizers $6.49 Billion Prevnar Franchise Faces a New Challenger (TIKR)
Oct-05-26 07:42PM	NVAX Stock Outruns Moderna As Vaxcytes Shot Clears A Late-Stage Test (Stocktwits) +30.70%
05:26PM	Vaxcyte stock falls on $1B dual offering launch (Investing.com)
04:28PM	Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes (GlobeNewswire)
02:37PM	PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit Blue-Sky Case (Stocktwits)
02:18PM	Drug stocks show rare weakness amid fears of vaccine competition (MarketWatch)
12:48PM	?? Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds Up in Study (The Wall Street Journal)
10:43AM	Loading…
10:43AM	Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That Sets a New Benchmark (TIKR)
10:39AM	Vaxcytes stock up after pneumococcal vaccine proves non-inferiority (Clinical Trials Arena)
10:32AM	Vaxcyte shares surge on late-stage vaccine trial success (Proactive)
10:23AM	Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck (Barrons.com)
10:01AM	Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study (Investor's Business Daily)
09:52AM	Vaxcyte skyrockets on near best-case pneumococcal vaccine data (BioPharma Dive)
08:10AM	Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial (InvestorsHub)
06:00AM	Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate (GlobeNewswire)
Oct-04-26 05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate (GlobeNewswire)
Sep-03-26 04:05PM	Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data (GlobeNewswire)
Aug-27-26 04:05PM	Vaxcyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-26 04:05PM	Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.31%
Jul-08-26 04:05PM	Vaxcyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-02-26 04:05PM	Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults (GlobeNewswire)
May-06-26 04:05PM	Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.84%
04:05PM	Loading…
Apr-07-26 04:05PM	Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-26 08:30AM	Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Mar-18-26 07:34PM	Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Mar-02-26 03:28PM	Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. (Barchart)
Feb-25-26 12:08AM	Vaxcyte Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... (GuruFocus.com)
Feb-24-26 04:05PM	Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-26 03:42AM	Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials (Insider Monkey)
Feb-18-26 07:39PM	Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating (Insider Monkey) +5.33%
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-16-26 12:23PM	Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) (Insider Monkey)
Feb-14-26 03:02PM	Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit (MarketBeat)
Feb-11-26 04:05PM	Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines (GlobeNewswire)
Feb-10-26 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 (GlobeNewswire)
Feb-05-26 04:05PM	Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-02-26 04:05PM	Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.15%
Jan-29-26 11:33PM	Vaxcyte Announces Pricing of $550 Million Public Offering (GlobeNewswire)
04:06PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-26-26 03:14AM	Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations (Insider Monkey)
Jan-23-26 10:12AM	Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase (Benzinga)
Jan-22-26 05:00PM	Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine (GlobeNewswire) +7.19%
Dec-22-25 08:19AM	This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. (Barrons.com)
06:50AM	What Makes Vaxcyte (PCVX) So Attractive (Insider Monkey)
Dec-08-25 07:00AM	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Dec-02-25 09:40AM	Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules (Zacks)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -8.24%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
09:36AM	Moderna Falls as FDA Vows to Impose New Vaccine Requirements (Bloomberg)
Nov-18-25 09:32AM	These 3 Stocks Are Using Buybacks to Signal Market Confidence (MarketBeat)
Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cowan Elvia	SVP, Finance & CAO	Nov 02 '26	Option Exercise	25.92	3,000	77,760	30,860	Nov 04 04:52 PM
Cowan Elvia	SVP, Finance & CAO	Nov 02 '26	Sale	60.92	3,000	182,753	27,860	Nov 04 04:52 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Nov 02 '26	Option Exercise	5.35	2,250	12,038	147,685	Nov 04 04:51 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Nov 02 '26	Sale	60.90	2,250	137,024	145,435	Nov 04 04:51 PM
Wassil Jim	Officer	Nov 02 '26	Proposed Sale	61.88	2,250	139,230		Nov 02 04:16 PM
Cowan Elvia	Officer	Nov 02 '26	Proposed Sale	61.88	3,000	185,640		Nov 02 04:07 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Oct 05 '26	Option Exercise	5.35	18,000	96,300	163,435	Oct 07 04:08 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Oct 05 '26	Sale	86.74	18,000	1,561,320	145,435	Oct 07 04:08 PM
Cowan Elvia	SVP, Finance & CAO	Oct 05 '26	Option Exercise	25.92	19,000	492,480	46,860	Oct 07 04:07 PM
Cowan Elvia	SVP, Finance & CAO	Oct 05 '26	Sale	86.74	19,000	1,648,060	27,860	Oct 07 04:07 PM
Cowan Elvia	Officer	Oct 05 '26	Proposed Sale	86.74	19,000	1,648,060		Oct 05 04:10 PM
Wassil Jim	Officer	Oct 05 '26	Proposed Sale	86.74	18,000	1,561,320		Oct 05 04:09 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Oct 01 '26	Option Exercise	5.35	2,250	12,038	147,685	Oct 02 04:05 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Oct 01 '26	Sale	56.67	2,250	127,513	145,435	Oct 02 04:05 PM
Wassil Jim	Officer	Oct 01 '26	Proposed Sale	56.73	2,250	127,642		Oct 01 04:13 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Sep 04 '26	Sale	61.16	1,381	84,462	152,228	Sep 09 05:46 PM
Wassil Jim	EVP, Chief Scientific Ofc, COO	Sep 09 '26	Sale	59.52	1,334	79,401	145,435	Sep 09 05:46 PM
Wassil Jim	Officer	Sep 09 '26	Proposed Sale	59.99	1,334	80,027		Sep 09 04:12 PM
Wassil Jim	Officer	Sep 04 '26	Proposed Sale	59.73	1,381	82,487		Sep 04 04:08 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 01 '26	Option Exercise	5.35	2,250	12,038	158,518	Sep 02 07:58 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 01 '26	Sale	61.07	3,477	212,352	155,041	Sep 02 07:58 PM
Wassil Jim	Officer	Sep 01 '26	Proposed Sale	60.29	3,477	209,628		Sep 01 04:09 PM
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Aug 05 '26	Option Exercise	24.79	17,000	421,430	93,756	Aug 05 07:01 PM
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Aug 05 '26	Sale	55.00	17,000	935,068	76,756	Aug 05 07:01 PM
Wassil Jim	CHIEF OPERATING OFFICER	Aug 03 '26	Option Exercise	5.35	2,250	12,038	159,791	Aug 05 04:59 PM
Wassil Jim	CHIEF OPERATING OFFICER	Aug 03 '26	Sale	53.86	2,250	121,195	157,541	Aug 05 04:59 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 03 '26	Option Exercise	5.35	10,000	53,500	115,176	Aug 05 04:58 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 03 '26	Sale	53.89	10,000	538,879	105,176	Aug 05 04:58 PM
Dhaliwal Harpreet S.	Officer	Aug 05 '26	Proposed Sale	55.00	17,000	935,000		Aug 05 04:06 PM
GUGGENHIME ANDREW	Officer	Aug 03 '26	Proposed Sale	53.99	10,000	539,900		Aug 03 04:16 PM
Wassil Jim	Officer	Aug 03 '26	Proposed Sale	53.99	2,250	121,478		Aug 03 04:14 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 27 '26	Option Exercise	2.03	16,198	32,882	469,445	Jul 28 04:10 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 27 '26	Sale	55.63	16,198	901,069	453,247	Jul 28 04:10 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 27 '26	Sale	55.65	2,000	111,307	133,215	Jul 28 04:10 PM
PICKERING GRANT	Officer	Jul 27 '26	Proposed Sale	54.77	18,198	996,704		Jul 27 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 06 '26	Option Exercise	5.35	10,000	53,500	114,395	Jul 06 07:31 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 06 '26	Sale	57.28	10,000	572,837	104,395	Jul 06 07:31 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jul 01 '26	Option Exercise	5.35	516	2,761	159,010	Jul 06 06:25 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jul 01 '26	Sale	56.33	2,250	126,736	156,760	Jul 06 06:25 PM
GUGGENHIME ANDREW	Officer	Jul 06 '26	Proposed Sale	57.76	10,000	577,600		Jul 06 04:06 PM
Wassil Jim	Officer	Jul 01 '26	Proposed Sale	58.13	2,250	130,792		Jul 01 04:02 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 26 '26	Sale	55.21	22,237	1,227,805	452,466	Jun 26 06:49 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 26 '26	Sale	55.23	2,000	110,465	134,215	Jun 26 06:49 PM
PICKERING GRANT	Officer	Jun 26 '26	Proposed Sale	53.77	24,237	1,303,223		Jun 26 04:05 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Option Exercise	1.79	225	403	497,164	Jun 18 08:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Sale	52.50	22,461	1,179,205	474,703	Jun 18 08:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Sale	52.50	2,000	105,000	135,215	Jun 18 08:08 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '26	Option Exercise	5.35	10,000	53,500	114,395	Jun 18 08:07 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '26	Sale	53.00	10,000	530,000	104,395	Jun 18 08:07 PM
GUGGENHIME ANDREW	Officer	Jun 18 '26	Proposed Sale	53.00	10,000	530,000		Jun 18 04:12 PM
PICKERING GRANT	Officer	Jun 18 '26	Proposed Sale	52.50	24,461	1,284,205		Jun 18 04:11 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jun 01 '26	Sale	49.52	2,250	111,416	158,494	Jun 03 04:59 PM
Wassil Jim	Officer	Jun 01 '26	Proposed Sale	51.01	2,250	114,772		Jun 01 04:26 PM
Wassil Jim	CHIEF OPERATING OFFICER	May 01 '26	Sale	56.83	2,250	127,870	160,744	May 01 05:37 PM
Wassil Jim	Officer	May 01 '26	Proposed Sale	57.26	2,250	128,835		May 01 04:17 PM
Cowan Elvia	SVP, Finance & CAO	Apr 07 '26	Option Exercise	25.92	3,000	77,760	31,975	Apr 08 04:32 PM
Cowan Elvia	SVP, Finance & CAO	Apr 07 '26	Sale	60.00	3,000	180,000	28,975	Apr 08 04:32 PM
Cowan Elvia	Officer	Apr 07 '26	Proposed Sale	60.00	3,000	180,000		Apr 07 04:24 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 01 '26	Sale	58.43	2,250	131,476	162,994	Apr 03 04:06 PM
Wassil Jim	Officer	Apr 01 '26	Proposed Sale	58.11	2,250	130,748		Apr 01 04:08 PM
Cowan Elvia	SVP, Finance & CAO	Mar 17 '26	Sale	55.57	1,892	105,147	28,975	Mar 18 07:03 PM
Cowan Elvia	Officer	Mar 17 '26	Proposed Sale	55.89	1,892	105,744		Mar 17 04:16 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Option Exercise	25.92	2,500	64,800	33,367	Mar 11 05:23 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Sale	58.59	2,500	146,482	30,867	Mar 11 05:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 10 '26	Sale	58.88	7,395	435,440	166,818	Mar 11 05:23 PM
Cowan Elvia	Officer	Mar 11 '26	Proposed Sale	58.62	2,500	146,550		Mar 11 04:06 PM
Wassil Jim	Officer	Mar 10 '26	Proposed Sale	58.47	7,395	432,386		Mar 10 04:12 PM
Cowan Elvia	SVP, Finance & CAO	Feb 26 '26	Option Exercise	25.92	7,716	199,999	31,931	Mar 02 08:08 PM
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Dec 31 '25	Sale	46.69	9,743	454,891	23,928	Jan 02 04:21 PM
HARPREET DHALIWAL	Officer	Dec 31 '25	Proposed Sale	46.69	9,743	454,893		Dec 31 04:32 PM
Cowan Elvia	SVP, FINANCE	Dec 23 '25	Sale	47.92	11,623	556,972	14,534	Dec 29 05:49 PM
ELVIA COWAN	Officer	Dec 23 '25	Proposed Sale	47.92	11,623	556,972		Dec 23 04:04 PM

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Co-FounderMr. Grant E. Pickering M.B.A.

President & CFOMr. Andrew L. Guggenhime M.B.A.

M.S.Mr. James T. Wassil M.B.A.

Chief Technical Operations OfficerMr. Harpreet S. Dhaliwal M.B.A.

Co-Founder & VP of ResearchDr. Jeff Fairman Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your Finviz experience